NCT05644054View on ClinicalTrials.gov

The Impact of THC on Pain Modulation in Fibromyalgia

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions
Fibromyalgia, Primary
Interventions
DRUG

THC

Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)

DRUG

Placebo

Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.

Trial Locations (1)

6997712

RECRUITING

Tel Aviv Medical Center, Tel Aviv

All Listed Sponsors
lead

Tel Aviv Medical Center

OTHER